Investment Thesis
Haemonetics faces material operational challenges with revenue stagnation and 42% net income decline YoY, offset partially by strong free cash flow generation and solid liquidity. Elevated debt levels (1.56x debt/equity) compound the risk profile given deteriorating profitability, suggesting the company requires near-term operational improvement to justify holding.
Strengths
- Exceptional free cash flow of $260.4M with 19.5% FCF margin demonstrates underlying business strength
- Strong liquidity position with 2.95x current ratio and $245.4M cash buffer
- Healthy gross margin of 59% and robust operating cash flow of $293.2M indicate core operations remain productive
- Interest coverage of 8.1x shows current ability to service debt obligations
Risks
- Revenue stagnation at 0% YoY growth signals loss of market momentum in medical devices sector
- Severe 42% net income and 38.1% EPS decline raises concerns about operational execution and margin compression
- Elevated debt-to-equity ratio of 1.56x combined with profit deterioration increases financial risk and limits strategic flexibility
- ROE of 12.2% and ROA of 4.1% are suboptimal for capital intensity, suggesting inefficient capital deployment during downturn
Key Metrics to Watch
- Quarterly revenue trends to confirm if stagnation reverses or accelerates downward
- Operating margin trajectory as management initiates cost restructuring initiatives
- Debt-to-equity ratio path—critical that leverage decreases as profitability recovers
- Free cash flow sustainability and any covenant compliance violations
Financial Metrics
Revenue
1.3B
Net Income
97.3M
EPS (Diluted)
$2.05
Free Cash Flow
260.4M
Total Assets
2.4B
Cash
245.4M
Profitability Ratios
Gross Margin
59.0%
Operating Margin
11.7%
Net Margin
7.3%
ROE
12.2%
ROA
4.1%
FCF Margin
19.5%
Balance Sheet & Liquidity
Current Ratio
2.95x
Quick Ratio
1.87x
Debt/Equity
1.56x
Debt/Assets
0.0%
Interest Coverage
8.12x
Long-term Debt
1.2B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-21T06:59:04.269013 |
Data as of: 2026-03-28 |
Powered by Claude AI